REMODEL findings suggest kidney protection is not diabetes-specific

Researchers presented findings from the REMODEL trial at the World Congress of Nephrology 2026 in Yokohama, Japan, suggesting that semaglutide's kidney-protective effects may work through biological pathways not limited to diabetes ^[1]. The trial was designed as a companion study to the earlier FLOW trial, which had already shown that semaglutide reduced cardiorenal complications in people with type 2 diabetes and chronic kidney disease ^[1]. While FLOW showed that the drug worked, REMODEL was built to explain why ^[1].

According to David Cherney, MD, PhD, one of the trial's investigators, REMODEL used MRI-based measures of kidney oxygenation as its main outcome, along with secondary measures including albuminuria, kidney function, fibrosis, intrarenal fat, and inflammatory markers ^[1]. Some participants also had paired kidney biopsies, which let researchers look directly at cellular changes inside the kidney ^[1]. The trial did not find an effect on kidney oxygenation, the primary endpoint, but it did turn up other findings ^[1].

Semaglutide reduced fat around and near the kidneys, known as perirenal and hilar fat, and improved markers tied to fibrosis, inflammation, and the health of blood vessel lining cells inside the kidney ^[1]. Cherney and co-presenter Brendon Neuen, MBBS, PhD, discussed the idea that fat around the kidney might contribute to kidney damage both by physically pressing on kidney structures and by releasing inflammatory signals from the fat tissue itself ^[1]. Both researchers said this idea needs more study but could be an underappreciated factor in kidney disease progression ^[1].

On a clinical level, semaglutide cut albuminuria — a marker of protein leaking into urine that signals kidney damage — by about 40% in the trial ^[1]. This benefit held up whether or not patients were also taking SGLT2 inhibitors, a different class of drugs already used to protect the kidneys, suggesting the two drug types may work through separate and complementary mechanisms ^[1].

Looking at the bigger picture, Cherney said the mechanisms seen in REMODEL — particularly those tied to inflammation and blood vessel dysfunction — are likely not specific to diabetes and could extend to kidney disease that has nothing to do with diabetes ^[1]. He argued for thinking about semaglutide as a kidney-directed therapy in its own right, separate from its effects on blood sugar or body weight ^[1].

Why it matters for patients

For people with type 2 diabetes and kidney disease already taking semaglutide, this research offers a possible explanation for benefits seen in earlier large trials like FLOW, beyond simple blood sugar or weight control ^[1]. That distinction matters because it suggests the drug's kidney effects are not just a side benefit of better glucose control.

The idea that these mechanisms might extend to non-diabetic kidney disease is described by the researchers as a hypothesis based on mechanistic signals, not a proven clinical benefit ^[1]. The sources do not report any clinical trial testing semaglutide specifically in people with kidney disease who do not have diabetes, so it is not yet known whether the drug would produce the same kidney protection in that group.

The finding that benefits were consistent regardless of SGLT2 inhibitor use may be relevant for patients already on that other class of kidney-protective drugs, since it points to possibly separate, additive mechanisms rather than overlapping ones ^[1].

What happens next

The sources do not specify a timeline for any follow-up trial testing semaglutide in non-diabetic kidney disease. The researchers noted that the fat-and-inflammation hypothesis and the biopsy-based cellular findings warrant further investigation, but no dates for additional studies are given in the available material ^[1].